No evidence of ccsvi in multiple sclerosis
-
Upload
uvcd -
Category
Presentations & Public Speaking
-
view
104 -
download
2
Transcript of No evidence of ccsvi in multiple sclerosis
NO EVIDENCE OF CCSVI
IN MULTIPLE SCLEROSIS
Jean-Baptiste Ricco
Vascular Surgery Department
University of Poitiers, France
CCSVI HYPOTHESIS
Raised venouspressures
Damage tointracranial
vascularendothelium
Incite inflammatoryresponse and breach of
blood‐brain barrierDevelop intoMS lesions
ZAMBONI CRITERIA
DOPPLER CRITERIA FOR CCSVI
ZAMBONI CRITERIA
DOPPLER CRITERIA FOR CCSVI
ZAMBONI CRITERIA
DOPPLER CRITERIA FOR CCSVI
ZAMBONI CRITERIA
DOPPLER CRITERIA FOR CCSVI
ZAMBONI CRITERIAZAMBONI CRITERIA
FOR CCSVIZAMBONI CRITERIA
FOR CCSVI
DOPPLER CRITERIA FOR CCSVI
ZAMBONI CRITERIA
2 POSITIVE ZAMBONI CRITERIA FOR CCSVI
DOPPLER CRITERIA FOR CCSVI
• CCSVI criteria fulfilled in all MS patients (n=109)
• and none of the controls (n=177)
CONCLUSIVE
ANALYSIS
MS CONTROL SENSITIVITY
SPECIFICITY
(95% CI)
≥ 2 POSITIVE
CRITERIA
109/109 0/177 100% (97-100)
100% (98-100)
• 65 MS patients compared to 235 controls
• “MS was strongly associated with CCSVI”
CRITERIA MS CONTROL Odds ratio
1 46/65 0/235 1123 (p<0.0001)
2 40/65 0/235 748 (p<0.0001)
3 24/65 1/235 137 (p<0.0001)
4 34/65 7/235 36 (p<0.0001)
5 36/65 25/235 10 (p<0.0001)
J Neurol Neurosurg Psychiatry 2009
METHODOLOGICAL ISSUES
• Potential observer bias in the US measurements,
• No description of blinding was provided
• The principal interpreting physician was identified
as PZ in the article.
• No description of any methods to limit
intraobserver or interobserver bias
• The rate of relapse-free patients improved from
27% to 50% (p<0.001)
• The rate of gadolinium-enhancing lesions on MRI
decreased from 50% to 12% (p<0.01)
• The Multiple Sclerosis Functional Composite score
improved significantly in this MS cohort. (p<0.01)
AFTER PTA
J VASC SURG 2009
MAJOR FLAWS
• Open-label study, no blinding of neurologists
• No control group
• A 66% of subjects with MS who had not previously
received DMT (disease-modifying-therapy) at the time
of baseline data collection were asked to start
standard DMT in order to enroll in the PTA study. A
major confounding factor
- Zamboni P. Curr Neurovasc Res 2007
- Zamboni P. J Neurol Neurosurg 2009
- Zamboni P. Funct Neurol 2009
-Zamboni P. J Vasc Surg 2009
-Zamboni P. Eur J Vasc Endovasc Surg 2011
- Baracchini C et al. Ann Neurol 2011
- Centonze D et al. Ann Neurol 2011
- Doepp F et al. Ann Neurol 2010
- Mayer CA et al. J Neurol Neurosurg 2011
- Zivadinov R et al. Neurology 2011
- Marder E et al. Arch Neurol 2011
- Tsivgoulis et al. Neurology 2011
- Auriel et aL. J Neurol Sciences 2011
- Blinkenberg et al. Acta Neurologica
Scandinavia 2012
- Comi et al (CosMo study) ECRIMS 2012
- Laukentaus SJ EJVES 2013
- Imperiale D Clinical Neurology and
Neurosurgery 2013
- Traboulsee AL Lancet 2013
CCSVI BY OTHER AUTHORS
FOREST PLOT
Estimate Lower bound Upper bound p-Value
1.56 0.95 2.56 0.08
Heterogeneity
tau^2 Q(df=12) Het. p-Value I^2
0.45 34.56 < 0.01 65%
• Case-control study
• 35 centers
• 1202 patients with MS
• 382 healthy controls
• 232 with other neurological diseases
G. Comi, G Mancardi for the CoSMo study
Sponsor: Italian Multiple Sclerosis Foundation
Illustration of the vascular abnormalities comprising the proposed entity chronic
cerebrospinal venous insufficiency. Figure adapted from R. Fox, Neurology 2011.
DIAGNOSIS of CCSVI
1
2
3
4
5
≥ 2 out the 5 CCSVI criteria have to be met
CENTRALIZED BLINDED EXAMINATION
• Duplex images were sent to an independent central
expert who performed a second blinded reading
• In case of disagreement, the exam was sent to the
two other central Duplex experts and the final
diagnosis was made by a majority
• Data collection and monitoring were carried out by an
independent organization and centralized
Independent central DU evaluation
Prof. Erwin Stolz, Neurologische Klinik-Giessen (Germany)
Prof. Massimo Del Sette, Ospedale S. Andrea - Italy
Dott. Giovanni Malferrari, Arcispedale S. Maria Nuova -Reggio Emilia - Italy
CCSVI PREVALENCE
3.26 2.13 3.10
0
2
4
6
8
10
12
14
16
18
20
MS HC OND
CC
SV
I p
rev
ale
nc
e (
%)
ns
MS: Multiple Sclerosis, HC: Healthy Controls, OND: Other Neurological Diseases
NS (p=0.30)
NS (p=0.99)
CoSMo STUDY
These results do not support the hypothesis of
the role of CCSVI as a potential causal factor in
the development of MS
CCSVI - THE FINAL CURTAIN
Traboulsee AL et al. Lancet, 2013 published on line October 9
This study aimed to establish the prevalence of
extracranial venous narrowing in people with
MS, unaffected full siblings, and unrelated
healthy volunteers.
Traboulsee AL et al. Lancet, 2013 published on line October 9
Blinded, case-control, multicentre study
177 adults: 79 with MS, 55 siblings, and 43
controls,
The authors assessed narrowing of the IJV and
azygous veins with catheter venography and
ultrasound criteria for CCSVI by Zamboni
Traboulsee AL et al. Lancet, 2013 published on line October 9
79 with MS
98 controls
177
enrolled
• Ultrasound
• Venography
All assessing study
team were masked to
participant status
MS
(N=79)
UNAFFECTED
SIBLINGS
(N=54)
HEALTHY
CONTRO
LS
(N=38)
P
VALUE
ULTRASOUND
≥2/5 POSITIVE
44% 31% 45% 0.27
ZAMBONI
VENOGRAPHY
CRITERIA
2% 2% 3% 1.0
> 50% NARROWING
ON VENOGRAPHY
74% 66% 70% 0.81
> 50% NARROWING
WITH ABNORMAL
FLOW
51% 45% 70% 0.51
0% 10% 20% 30% 40% 50% 60%
0
1
2
3
4
5
Controls Siblings MS
① High-resolution B-mode
anomalies
② Reflux in the deep cerebral
veins / Flow not doppler-
detectable in the IJV/ vertebral
vein
③ Reflux in the IJV / vertebral
veins
④ Reversed postural control of
the main cerebral venous
outflow
CCSVI ULTRASOUND
CRITERIA
The sensitivity of ultrasound CCSVI criteria for detection of >50% narrowing seen on catheter venography was 0.40 [0.31-0.50]
The agreement was equally poor in MS patients and healthy controls.
This review provides no evidence
that extracranial venous anatomy
differs between patients with MS
and healthy controls
These results also challenge both
the validity of ultrasound for the
purpose of detecting CCSVI and its
existence as a disorder
The angioplasty for CCSVI which was
tendentiously termed liberation
treatment earned Internet coverage and
kindled the hopes of desesperate
patients.
It is clear that no reason exists to
allocate further resources to CCSVI
research, be they financial or
intellectual
Liberation Treatment India
A no Obligation, No Cost, Patient Helpline for Liberation
Treatment in India
www.liberationtreatmentindia.co
m
For more info or any queries write to us at: [email protected]
US/Canada Toll Free Number:1-888-771-6965International Helpline Number: +91-9198993637